How HIV's Vif protein targets the cell regulator PP2A‑B56
Cellular Determinants and Function Consequences of PP2A-B56 Degradation by HIV-1 Vif
This project learns how HIV's Vif protein destroys a cellular regulator called PP2A‑B56 and how that helps HIV multiply in CD4+ T cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11325380 on NIH RePORTER |
What this research studies
Researchers will use protein interaction methods to find which cellular proteins bind to PP2A‑B56 when it is targeted by Vif. They will run a genome‑wide CRISPR/Cas9 screen to find genes that control degradation of APOBEC3 and PP2A‑B56. Individual phosphorylation sites controlled by PP2A‑B56 will be tested for their effect on HIV replication in primary human CD4+ T cells. Most work is done in laboratory cell systems and human-derived immune cells rather than as a treatment for patients.
Who could benefit from this research
Good fit: People living with HIV or healthy volunteers who can give blood for isolation of primary CD4+ T cells would be the most relevant donors for this work.
Not a fit: Patients seeking immediate changes to their clinical care or new treatment options should not expect direct benefit because this is basic laboratory research.
Why it matters
Potential benefit: If successful, this work could reveal new cellular targets that lead to therapies blocking HIV replication.
How similar studies have performed: Previous lab studies established that Vif targets APOBEC3 and recent work has shown Vif can also target PP2A‑B56, but translating those findings to therapies is still new.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Johnson, Jeffrey R — Icahn School of Medicine at Mount Sinai
- Study coordinator: Johnson, Jeffrey R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.